NASDAQ:KALV - Kalvista Pharmaceuticals Stock Price, Forecast & News

Kalvista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) posted its quarterly earnings results on Tuesday, December, 3rd. The specialty pharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $0.22. The specialty pharmaceutical company earned $3.92 million during the quarter, compared to analyst estimates of $3.23 million. Kalvista Pharmaceuticals had a negative return on equity of 25.70% and a negative net margin of 182.37%. View Kalvista Pharmaceuticals' Earnings History.

Kalvista Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Kalvista Pharmaceuticals.

4 equities research analysts have issued 1-year target prices for Kalvista Pharmaceuticals' shares. Their forecasts range from $28.00 to $31.00. On average, they anticipate Kalvista Pharmaceuticals' share price to reach $30.00 in the next twelve months. This suggests a possible upside of 61.6% from the stock's current price. View Analyst Price Targets for Kalvista Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kalvista Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kalvista Pharmaceuticals.

Media coverage about KALV stock has been trending positive on Monday, according to InfoTrie. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Kalvista Pharmaceuticals earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Kalvista Pharmaceuticals.

Kalvista Pharmaceuticals saw a increase in short interest in the month of December. As of December 31st, there was short interest totalling 877,600 shares, an increase of 11.3% from the December 15th total of 788,700 shares. Based on an average daily trading volume, of 154,400 shares, the days-to-cover ratio is presently 5.7 days. Approximately 7.0% of the shares of the company are sold short. View Kalvista Pharmaceuticals' Current Options Chain.

Some companies that are related to Kalvista Pharmaceuticals include NextCure (NXTC), Athenex (ATNX), Karyopharm Therapeutics (KPTI), Enanta Pharmaceuticals (ENTA), Portola Pharmaceuticals (PTLA), ZEALAND PHARMA/S (ZEAL), Rocket Pharmaceuticals (RCKT), Opko Health (OPK), Phibro Animal Health (PAHC), Dermira (DERM), IGM Biosciences (IGMS), XBiotech (XBIT), Revance Therapeutics (RVNC), RAPT Therapeutics (RAPT) and Gossamer Bio (GOSS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Kalvista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Corbus Pharmaceuticals (CRBP), Viking Therapeutics (VKTX), GALAPAGOS NV/S (GLPG), Ritter Pharmaceuticals (RTTR), BIOLINERX LTD/S (BLRX), Progenics Pharmaceuticals (PGNX) and SCYNEXIS (SCYX).

Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of KALV stock can currently be purchased for approximately $18.56.

Kalvista Pharmaceuticals has a market capitalization of $330.92 million and generates $16.13 million in revenue each year. The specialty pharmaceutical company earns $-20,820,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. Kalvista Pharmaceuticals employs 33 workers across the globe.View Additional Information About Kalvista Pharmaceuticals.

The official website for Kalvista Pharmaceuticals is http://www.kalvista.com/.

Kalvista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]